These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. Bell C; Graham J; Earnshaw S; Oleen-Burkey M; Castelli-Haley J; Johnson K J Manag Care Pharm; 2007 Apr; 13(3):245-61. PubMed ID: 17407391 [TBL] [Abstract][Full Text] [Related]
8. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes. Yano H; Gonzalez C; Healy BC; Glanz BI; Weiner HL; Chitnis T Mult Scler Relat Disord; 2019 Oct; 35():119-127. PubMed ID: 31374460 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain. Dembek C; White LA; Quach J; Szkurhan A; Rashid N; Blasco MR Eur J Health Econ; 2014 May; 15(4):353-62. PubMed ID: 23615954 [TBL] [Abstract][Full Text] [Related]
10. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy. Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP Mult Scler; 2001 Dec; 7(6):349-53. PubMed ID: 11795454 [TBL] [Abstract][Full Text] [Related]
11. The Australian Multiple Sclerosis (MS) immunotherapy study: a prospective, multicentre study of drug utilisation using the MSBase platform. Jokubaitis VG; Spelman T; Lechner-Scott J; Barnett M; Shaw C; Vucic S; Liew D; Butzkueven H; Slee M; PLoS One; 2013; 8(3):e59694. PubMed ID: 23527252 [TBL] [Abstract][Full Text] [Related]
12. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre. Río J; Tintoré M; Nos C; Téllez N; Galán I; Montalban X J Neurol; 2005 Jul; 252(7):795-800. PubMed ID: 15772741 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of disease modifiying drugs (interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients. Sánchez-de la Rosa R; Sabater E; Casado MA; Arroyo R J Med Econ; 2012; 15(3):424-33. PubMed ID: 22217249 [TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States. Hernandez L; Guo S; Kinter E; Fay M J Med Econ; 2016 Jul; 19(7):684-95. PubMed ID: 26947984 [TBL] [Abstract][Full Text] [Related]
15. Utilization of peginterferon-β-1a in the real-world practice for relapsing-remitting multiple sclerosis. Moccia M; Santoni L; Vaccari I; Affinito G; Caliendo D; Rubba F; Lanzillo R; Triassi M; Brescia Morra V; Palladino R Eur Rev Med Pharmacol Sci; 2024 Jan; 28(1):411-418. PubMed ID: 38235893 [TBL] [Abstract][Full Text] [Related]
16. What is new in the treatment of multiple sclerosis? Weinstock-Guttman B; Jacobs LD Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827 [TBL] [Abstract][Full Text] [Related]
17. Swiss analysis of multiple sclerosis: a multicenter, non-interventional, retrospective cohort study of disease-modifying therapies. Gobbi C; Zecca C; Linnebank M; Müller S; You X; Meier R; Borter E; Traber M Eur Neurol; 2013; 70(1-2):35-41. PubMed ID: 23689307 [TBL] [Abstract][Full Text] [Related]
18. Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study. Kleinschnitz C; Niemczyk G; Rehberg-Weber K; Wernsdörfer C Int J Mol Sci; 2015 Jul; 16(7):15271-86. PubMed ID: 26154767 [TBL] [Abstract][Full Text] [Related]
19. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935 [TBL] [Abstract][Full Text] [Related]
20. Different clinical response to interferon beta and glatiramer acetate related to the presence of oligoclonal IgM bands in CSF in multiple sclerosis patients. Casanova B; Lacruz L; Villar ML; Domínguez JA; Gadea MC; Gascón F; Mallada J; Hervás D; Simó-Castelló M; Álvarez-Cermeño JC; Calles C; Olascoaga J; Ramió-Torrentà L; Alcalá C; Cervelló A; Boscá I; Pérez-Mirallles FC; Coret F Neurol Sci; 2018 Aug; 39(8):1423-1430. PubMed ID: 29882169 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]